Novavax | NVAX - Cash And Equivalent

Stock Price
8.70
Daily Change
0.28 3.33%
Monthly
6.23%
Yearly
6.23%
Q1 Forecast
8.43

Novavax reported $268.02M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Adma Biologics USD 61.38M 28.9M Sep/2025
Agenus USD 3.46M 6.08M Sep/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
BioCryst Pharmaceuticals USD 84.08M 3.95M Sep/2025
Cassava Sciences USD 106.08M 6.3M Sep/2025
Geron USD 79.99M 389K Sep/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
MannKind USD 127.39M 70.39M Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Minerva Neurosciences USD 12.29M 2.96M Sep/2025
Moderna USD 2.6B 1.46B Dec/2025
Novartis USD 9.56B 2.9B Sep/2025
Novavax USD 268.02M 14.28M Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Sarepta Therapeutics USD 613.08M 102.48M Sep/2025
TG Therapeutics USD 178.32M 100.54M Sep/2025